Intermittent Administration News Today

1. The MERCY trial revealed that continuous infusion of meropenem does not confer a significant advantage over intermittent administration in reducing mortality and preventing new antibiotic-resistant bacteria in patients with either septic shock or sepsis. 2. This randomized control trial provides contrary evidence to previous systematic reviews and meta-analyses that found better outcomes with continuous

There has been a concerted effort over the past 2 decades to improve sepsis outcomes by enhancing recognition of sepsis and decreasing the time to administratio

This randomized clinical trial compares the effect of continuous administration of meropenem vs intermittent administration on a composite outcome of mortality